NewsBenzingaReported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW Benzinga 2026.10.19 07:01 (GMT+0) Open on Benzinga Other news Tolan snags $30M for its AI companion that helps users navigate life Replika’s founder built the AI assistant she pitched at Disrupt 12 years ago Tenstorrent hits $6.2B valuation to scale open-weight AI chips Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic Rain Says Western Union's Stablecard Is Live in 37 Markets FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
